+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Myasthenia Gravis Treatment Market (2023-2028) by Type, End-User, and Geography, Competitive Analysis, Impact of Economic Slowdown & Impending Recession with Ansoff Analysis

  • PDF Icon


  • 154 Pages
  • January 2023
  • Region: Global
  • Infogence Global Research
  • ID: 5748979

The estimated prevalence of myasthenia gravis is approximately 20 cases per 100,000 population

The Global Myasthenia Gravis Treatment Market is estimated to be USD 1.33 Bn in 2023 and is expected to reach USD 1.89 Bn by 2028, growing at a CAGR of 7.3%.

Market Dynamics

Market dynamics are forces that impact the prices and behaviors of the stakeholders. These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service. Forces of Market Dynamics may be related to macro-economic and micro-economic factors. There are dynamic market forces other than price, demand, and supply. Human emotions can also drive decisions, influence the market, and create price signals.

As the market dynamics impact the supply and demand curves, decision-makers aim to determine the best way to use various financial tools to stem various strategies for speeding the growth and reducing the risks.

Market Segmentations

The Global Myasthenia Gravis Treatment Market is segmented based on Type, End-User, and Geography.
  • By Type, the market is classified into Medication and Surgery.
  • By End-User, the market is classified into Clinics and Hospitals.
  • By Geography, the market is classified into Americas, Europe, Middle-East & Africa, and Asia-Pacific.

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are AbbVie, Inc., GSK PLC, Novartis Ag, Pfizer, Inc., Bausch Health Companies, Inc., etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes a Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

The report presents a detailed Ansoff matrix analysis for the Global Myasthenia Gravis Treatment Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.

The analyst analyses the Global Myasthenia Gravis Treatment Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.

Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Myasthenia Gravis Treatment Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter's 5 forces model and the Ansoff Matrix. In addition, the impact of COVID-19 and impact of economic slowdown & impending recession on the market are also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using Positioning Quadrants, the analyst's competitive positioning tool.

Report Highlights:

  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Myasthenia Gravis Treatment Market

What is the estimated value of the Global Myasthenia Gravis Treatment Market?

The Global Myasthenia Gravis Treatment Market was estimated to be valued at $1.33 Billion in 2023.

What is the growth rate of the Global Myasthenia Gravis Treatment Market?

The growth rate of the Global Myasthenia Gravis Treatment Market is 7.3%, with an estimated value of $1.89 Billion by 2028.

What is the forecasted size of the Global Myasthenia Gravis Treatment Market?

The Global Myasthenia Gravis Treatment Market is estimated to be worth $1.89 Billion by 2028.

Who are the key companies in the Global Myasthenia Gravis Treatment Market?

Key companies in the Global Myasthenia Gravis Treatment Market include AbbVie, Inc., Alexion Pharmaceutical, Inc., Argenx SE, Avadel Pharmaceuticals, PLC, Bausch Health Companies, Inc., Catalyst Pharmaceuticals, Inc., CSL Behring Ag, F.Hoffmann, La Roche Ag and Avadel Pharmaceuticals PLC.

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders

2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study

3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations, and Outlook

4 Market Dynamics
4.1 Drivers
4.1.1 Growing Geriatric Population Across the Globe
4.1.2 Increasing Cases of Swollen Eyes Due to Myasthenia Gravis
4.1.3 Rising Clinical Trials for Treatment
4.2 Restraints
4.2.1 High Cost Associated with the Treatment
4.3 Opportunities
4.3.1 Improving Healthcare Infrastructure
4.3.2 Upsurge in the Number of Pipeline Studies for Drug Development
4.4 Challenges
4.4.1 Side Effects Associated with Drugs

5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 PESTLE Analysis
5.4 Impact of COVID-19
5.5 Impact of Economic Slowdown & Impending Recession
5.6 Ansoff Matrix Analysis

6 Global Myasthenia Gravis Treatment Market, By Type
6.1 Introduction
6.2 Medication
6.3 Surgery

7 Global Myasthenia Gravis Treatment Market, By End-Users
7.1 Introduction
7.2 Clinics
7.3 Hospitals

8 Americas' Myasthenia Gravis Treatment Market
8.1 Introduction
8.2 Argentina
8.3 Brazil
8.4 Canada
8.5 Chile
8.6 Colombia
8.7 Mexico
8.8 Peru
8.9 United States
8.10 Rest of Americas

9 Europe's Myasthenia Gravis Treatment Market
9.1 Introduction
9.2 Austria
9.3 Belgium
9.4 Denmark
9.5 Finland
9.6 France
9.7 Germany
9.8 Italy
9.9 Netherlands
9.10 Norway
9.11 Poland
9.12 Russia
9.13 Spain
9.14 Sweden
9.15 Switzerland
9.16 United Kingdom
9.17 Rest of Europe

10 Middle East and Africa's Myasthenia Gravis Treatment Market
10.1 Introduction
10.2 Egypt
10.3 Israel
10.4 Qatar
10.5 Saudi Arabia
10.6 South Africa
10.7 United Arab Emirates
10.8 Rest of MEA

11 APAC's Myasthenia Gravis Treatment Market
11.1 Introduction
11.2 Australia
11.3 Bangladesh
11.4 China
11.5 India
11.6 Indonesia
11.7 Japan
11.8 Malaysia
11.9 Philippines
11.10 Singapore
11.11 South Korea
11.12 Sri Lanka
11.13 Thailand
11.14 Taiwan
11.15 Rest of Asia-Pacific

12 Competitive Landscape
12.1 Competitive Quadrant
12.2 Market Share Analysis
12.3 Strategic Initiatives
12.3.1 M&A and Investments
12.3.2 Partnerships and Collaborations
12.3.3 Product Developments and Improvements

13 Company Profiles
13.1 AbbVie, Inc.
13.2 Alexion Pharmaceutical, Inc.
13.3 Argenx SE
13.4 Avadel Pharmaceuticals, PLC
13.5 Bausch Health Companies, Inc.
13.6 Catalyst Pharmaceuticals, Inc.
13.7 CSL Behring Ag
13.8 F.Hoffmann-La Roche Ag
13.9 Avadel Pharmaceuticals PLC
13.10 Fresenius Kabi Ag
13.11 GSK PLC
13.12 Grifols SA
13.13 Lupin Pharmaceuticals Pvt. Ltd.
13.14 Mitsubishi Tanabe Pharma Corp.
13.15 Novartis Ag
13.16 Pfizer, Inc.
13.17 Sandoz, Inc.
13.18 Shire PLC
13.19 Sun Pharmaceuticals Industries Ltd.
13.20 Taj Pharmaceuticals Ltd.
13.21 Takeda Pharmaceuticals Co. Ltd.
13.22 Troikaa Pharmaceuticals Ltd.
13.23 Bausch Health Companies, Inc.
13.24 Zydus Cadila Healthcare Ltd.

14 Appendix
14.1 Questionnaire

Companies Mentioned

  • AbbVie, Inc.
  • Alexion Pharmaceutical, Inc.
  • Argenx SE
  • Avadel Pharmaceuticals, PLC
  • Bausch Health Companies, Inc.
  • Catalyst Pharmaceuticals, Inc.
  • CSL Behring Ag
  • F.Hoffmann-La Roche Ag
  • Avadel Pharmaceuticals PLC
  • Fresenius Kabi Ag
  • Grifols SA
  • Lupin Pharmaceuticals Pvt. Ltd.
  • Mitsubishi Tanabe Pharma Corp.
  • Novartis Ag
  • Pfizer, Inc.
  • Sandoz, Inc.
  • Shire PLC
  • Sun Pharmaceuticals Industries Ltd.
  • Taj Pharmaceuticals Ltd.
  • Takeda Pharmaceuticals Co. Ltd.
  • Troikaa Pharmaceuticals Ltd.
  • Bausch Health Companies, Inc.
  • Zydus Cadila Healthcare Ltd.